Management of NMIBC: Practical Solutions for Common Problems Webcast (2020)

This course will review the most recent AUA practice guidelines for non-muscle-invasive bladder cancer and detail strategies to manage common clinical predicaments involved in the management of these tumors. Specifically we will review: the AUA guidelines; risk stratification and use of cystectomy; selection of the optimal intravesical agent at the right schedule; and treatment of toxicity from intravesical therapy. Practical solutions will be presented that can be readily integrated into the office setting. Emphasis is placed on the evaluation of real clinical cases with open audience participation.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners & Physician Assistants)

Learning Objectives

After completing this activity, participants will be able to:

  1. Implement current AUA NMIBC practice guidelines into the office setting.
  2. Identify the best intravesical agent and duration of therapy for low, intermediate, and high-risk settings and what to do during a BCG shortage.
  3. Identify methods to treat significant toxicities from various intravesical therapies.
  4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.
  5. Discuss the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and become familiar with current clinical trial designs.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
07/31/2020
Course expires: 
07/31/2021
Part of: 
Summer School Webcast Series - CME (2020)
Rating: 
0

Education Council Disclosures

PDF icon Education Council & COI Reviewer Disclosures.pdf

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Kamal Pohar, MD

has no relevant financial relationships to disclose at this time.
Faculty(s)

Ashish Kamat, MD

has a financial relationship (Independent contractor) with BioClin Therapeutics;.
has a financial relationship (Independent contractor) with US Biotest;.
has a financial relationship (Independent contractor) with Medac;.
has a financial relationship (Independent contractor) with Nucleix;.
has a financial relationship (Independent contractor) with Photocure;.
has a financial relationship (Independent contractor) with MDxHealth;.
has a financial relationship (Independent contractor) with Cold Genesys;.
has a financial relationship (Independent contractor) with Ferring;.
has a financial relationship (Independent contractor) with Asieris;.
has a financial relationship (Independent contractor) with TMC Innovation;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Other) with FKD;.
has a financial relationship (Independent contractor) with Imagin;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Arquer;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Theralase;.
has a financial relationship (Independent contractor) with Roviant;.
has a financial relationship (Independent contractor) with Eisai;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Cepheid;.
has a financial relationship (Independent contractor) with IBCG;.
has a financial relationship (Independent contractor) with Abbott Molecular;.
has a financial relationship (Independent contractor) with Sessen Bio;.

Cheryl Lee, MD

has a financial relationship (Independent contractor) with merck;.

J. Witjes, MD

has a financial relationship (Independent contractor) with Spectrum, Taris, BioCanCell, Cepheid, Nucleix;.
has a financial relationship (Independent contractor) with BMS, Tocagen, MSD, Roche;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.50 hours

Release Date: August, 2020
Expiration Date: August, 2021

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.